Physician profile
Mitchell E Klausner
NPI 1083698682
$4,573.28
in general payments reported to CMS, 2019-2025
31 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $140 · 2021: $579 · 2022: $680 · 2023: $823 · 2024: $764 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,207.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $767.94 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $520.88 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $496.87 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $388.26 | 2019-2024 | |
| Glaxosmithkline, LLC. | $319.70 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $245.25 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $231.43 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Dexcom, INC. | $220.57 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $201.81 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.71 | 2019-2025 | Jardiance, Ofev |
| Abbvie INC. | $178.88 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $138.08 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $82.71 | 2023-2024 | Onpattro, Givlaari |
| Esperion Therapeutics, INC. | $81.12 | 2021-2024 | Nexletol |
| Astellas Pharma US INC | $75.90 | 2019-2024 | Veozah |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $71.71 | 2019-2021 | |
| Amarin Pharma, INC. | $44.60 | 2019-2020 | |
| Exact Sciences Corporation | $37.39 | 2025 | The Cologuard Plus Collection Kit |
| Abbott Laboratories | $31.95 | 2022-2023 | Freestyle Libre 2 |
| Tolmar, INC. | $30.80 | 2024-2025 | Jatenzo |
| Kowa Pharmaceuticals America, INC. | $29.19 | 2021-2022 | |
| Seqirus USA INC | $29.03 | 2022 | |
| Gilead Sciences, INC. | $24.12 | 2019 | |
| Sanofi Pasteur INC. | $23.63 | 2019-2020 | |
| Daiichi Sankyo INC. | $20.27 | 2024 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $18.06 | 2024 | Uptravi, Opsumit |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.15 | 2022 | |
| Ibsa Pharma INC. | $15.66 | 2023 | Tirosint, Licart |
| Takeda Pharmaceuticals U.S.A., INC. | $14.83 | 2024 | Vpriv |
| Bausch Health US, LLC | $13.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Klausner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.